Since 1923, we have been focused on innovation and leadership in diabetes care. Today we have a broad portfolio of medicines.
Since the launch of our first pen needle in 1985, we have been committed to enhancing injection experience by putting technology in patient hands.
Access information on our products for rare bleeding disorders, growth hormone-related disorders, and women's health.
Find information on our treatment for chronic weight management in adults who are overweight with one weight-related comorbidity or obesity.
The link above used in conjunction with the FDA-approved product labeling may be used to determine U.S. patents associated with the corresponding U.S. marketed product.
Improving Patient's Lives
For nearly a century, Novo Nordisk has focused on diabetes care and areas of unmet needs, keeping the patient at the center of everything we do.
At Novo Nordisk our leadership represents a broad, diverse array of
life experiences with one very important commonality: a dedication to
Doug Langa Executive Vice
President North America Operations and President of Novo Nordisk
Steve Albers Corporate Vice
President Market Access
Corporate Vice President Legal and Corporate Affairs
Pia D' Urbano
Corporate Vice President Biopharmaceuticals
Jill Fallows Macaluso
Corporate Vice President Chief Compliance Officer
Maryellen McQuade Corporate
Vice President Human Resources
David Moore Senior Vice
Ulrich Otte Senior Vice
President Finance & Operations
Anne Phillips, MD
Senior Vice President Clinical Medical and Regulatory Affairs